ArticleCommunications medicine2026
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Funding
Abstract
backgroundHepatectomy is considered advisable for some patients with intermediate or advanced hepatocellular carcinoma (HCC). The efficacy and safety of neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors (neoadjuvant triple therapy) for these patients remain unclear.
methods583 patients who met the resectable criteria and were assigned to receive neoadjuvant triple therapy (n = 205) or direct hepatectomy (n = 378) at 20 Chinese medical centers (2019-2023) were retrospectively compared in terms of overall survival (OS), event-free survival (EFS), adverse events, and postoperative complications. The subgroup stratified includes 106 patients who underwent neoadjuvant triple therapy followed by hepatectomy or 99 patients who received it without subsequent hepatectomy.
resultsCompared to patients who undergo direct hepatectomy, those who receive neoadjuvant triple therapy show significantly higher OS (hazard ratio [HR] 0.70, 95%CI 0.53-0.92) and significantly longer median EFS (19.7 vs 10.9 months). Similar results are obtained after propensity score matching (PSM). Among patients who undergo hepatectomy, those with prior neoadjuvant triple therapy have significantly better OS (HR 0.45, 95%CI 0.31-0.66) and EFS (HR 0.49, 95%CI 0.38-0.63) than those with direct hepatectomy. Similar results are obtained after PSM. Among patients who receive neoadjuvant triple therapy, OS is significantly better among those who subsequently underwent hepatectomy (HR 0.40, 95%CI 0.24-0.67). neoadjuvant triple therapy results in a complete pathologic response rate of 34.0%. However, the regimen is associated with high rates of serious adverse events and postoperative complications, including hepatic insufficiency, bile leakage, and ascites.
conclusionsNeoadjuvant triple therapy offers OS and EFS benefits for patients with resectable intermediate or advanced HCC, but is associated with an increased risk of adverse events and postoperative complications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.